Walkers acts as Cayman Islands counsel to MoonLake Immunotherapeutics AG on its Business Combination with Helix Acquisition Corp.

Walkers is pleased to have acted as Cayman Islands counsel to MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company specialising in the development of therapies for inflammatory skin and joint diseases, in connection with its business combination with Helix Acquisition Corp., a special purpose acquisition company.

The business combination results in MoonLake becoming a publicly listed company, with the combined company having a pro forma enterprise value of approximately $620 million. As part of the transaction, MoonLake raised a $115 million fully committed PIPE from institutional investors. MoonLake will be led by an international team of immunology experts, whose focus will be on accelerating the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F.

Walkers was instructed by onshore law firm Gibson, Dunn & Crutcher LLP and was led by Cayman Islands partner Bicrom Das with assistance from associates Sam Francis, Daniel Walford and Aoife Murphy.

Bicrom DasPartnerT +1 345 814 4606bicrom.das@walkersglobal.com
Sam FrancisAssociateT +1 345 914 6361 sam.francis@walkersglobal.com
Aoife MurphyAssociateT +1 345 814 6859aoife.murphy@walkersglobal.com

Related Content